"Weight-loss Effect Comparable to Retatrutide Observed"

Alteogen announced on the 9th that its internally developed once-monthly obesity treatment demonstrated a weight-loss effect in animal pharmacokinetic studies comparable to Eli Lilly's next-generation obesity drug retatrutide.


Alteojen Corporate Identity

Alteojen Corporate Identity

View original image

On this day, Alteogen released an update on the development progress of its once-monthly obesity treatment based on its "ultra-long-action" platform. Unlike existing long-acting platforms that extend the dosing interval to once a week, this platform, which is being developed based on Alteogen's protein engineering technology, is characterized by extending the interval further to once a month.


Alteogen stated that the once-monthly obesity treatment candidate, whose development was made public last year, showed a long half-life and sustained drug concentration in animal pharmacokinetic studies. In the latest pharmacodynamic study, the company used an obese rat model to evaluate the weight-loss effect and the pattern of weight regain after discontinuation of dosing. According to the company, the results showed not only a weight-loss effect at a level similar to that of retatrutide, which was used as a comparator, but also a trend toward mitigation of rapid weight regain even after treatment was stopped.


Currently, the global obesity treatment market is centered on once-weekly dosing as the standard of care. Retatrutide, a once-weekly subcutaneous injection developed by Eli Lilly, has drawn attention as a next-generation candidate surpassing Wegovy and Mounjaro, after demonstrating a 29% weight-loss effect in clinical trials. Alteogen expects that, based on the excellent pharmacological profile confirmed in this study and the convenience of once-monthly dosing, it will be able to secure competitiveness.


Jeon Taeyeon, CEO of Alteogen, said, "These results suggest that the obesity treatment applying our new platform technology possesses excellent weight-loss efficacy and favorable characteristics for weight maintenance," adding, "We expect it to evolve into a competitive pipeline in the global obesity treatment market."



Meanwhile, Alteogen plans to expand its next-generation pipeline by pursuing both open innovation and in-house development, funded by the capital secured through licensing-out of its Hybrozyme platform-based technology. The company will also gradually promote in-house production facilities and the expansion of shareholder return policies.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing